Medcan Australia

What Medcan Australia does

Medcan Australia is a vertically integrated, Queensland-based medicinal cannabis company founded in 2016 that operates across the full value chain — indoor cultivation, GMP manufacturing, GACP post-harvest production, pharmaceutical wholesaling, and import/export of medicinal cannabis products. The company is the 13th holder of an Office of Drug Control (ODC) Cultivation and Production licence (granted November 2017) and maintains a suite of federal and state licences including ODC Import/Export, DAWR and QLD Health Wholesaling. Its Brisbane facility uses automated environmental controls (humidity, temperature, VPD, CO2, fertigation, light intensity) and custom-designed horizontal linear airflow drying rooms to deliver consistent, year-round pharmaceutical-grade output with annual capacity of up to 6,000 kg of dried finished product. Core products are TGO93-compliant MEDCAN branded medicinal cannabis SKUs.

The company monetises through one-time product sales, wholesale distribution margins (via its own pharmacy-channel platform and the Greensaver Distribution subsidiary established in 2024), and a recurring compassionate-pricing subsidy program. Its go-to-market is B2B2C: cultivation and manufacturing output flows through Australian pharmacies via an online ordering portal and through the Cann I Help doctor-led network, reaching patients on TGA Special Access Scheme prescriptions. Reported financial milestones include 493% revenue growth in FY20-21, 31% EBITDA margin, 17% net profit after tax, and a 19% dividend to shareholders — making Medcan the first fully licensed Australian medicinal cannabis company to pay a dividend. Strategic partnerships include the CMOS observational study (20,000-patient target) and the Cann I Help Compassionate Access Program (15/30/50% subsidies for eligible patients). Medcan is a wholly owned operating subsidiary of Medcan Group.

Name

Medcan Australia

Legal name

Medcan Australia

Website

https://medcanaustralia.com.au

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

51–100 employees

Short description

Medcan Australia is a vertically integrated, Queensland-based medicinal cannabis producer (founded 2016) that cultivates, GMP-manufactures, wholesales and distributes TGO93-compliant cannabis products through Australian pharmacies and the Cann I Help doctor network.

Ownership category

akta.pro rank

Product category

Medicinal Cannabis Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Medical Cannabis Dispensaries (CRANAFAB)

akta.pro secondary industries

Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services) (CRANAFAI), Dispensary-Owned Online Ordering & Delivery (Direct-to-Consumer) (CRANAGAE)

Keywords

• Medicinal cannabis cultivation
• Pharmaceutical manufacturing
• Cannabis product distribution
• GMP manufacturing services
• Medicinal cannabis wholesale

Headquarters

HQ city

Springfield

HQ country

Australia

HQ region

Oceania

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Medicinal Cannabis Product Sales: Revenue from cultivation, manufacture, import, export, wholesaling and distribution of medicinal cannabis products. The company sells MEDCAN branded products TGO93 compliant through pharmacy and prescriber channels.
2. Wholesale and Distribution: Full-service pharmaceutical wholesaling and distribution operations supplying pharmacies across Australia with medicinal cannabis products.
3. Compassionate Access Program: Subsidy program offering 15, 30 or 50 per cent subsidies across a range of treatments for eligible patients, supported through partnership with Cann I Help.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Medcan Australia is a vertically integrated medicinal cannabis company that cultivates, manufactures, wholesales, and distributes TGO93-compliant medicinal cannabis products in Australia. The company operates a state-of-the-art indoor automated cultivation facility with capacity up to 6,000kgs of dried finished product annually, alongside GMP and GACP compliant production processes. It serves pharmacies, GPs, and specialists through wholesale distribution, an online ordering platform, and Australia's first Compassionate Access Program offering patient subsidies.

Product overview

Medcan Australia operates a vertically integrated medicinal cannabis business offering cultivation, production, GMP manufacturing, and pharmaceutical wholesaling/distribution services. The core product portfolio centers on MEDCAN branded TGO93 compliant medicinal cannabis products. The company also provides post-harvest production under GACP standards. Key services include indoor automated cultivation with environmental control systems, pharmaceutical-grade manufacturing, and Australia's first Compassionate Access Program offering subsidies to eligible patients.

Differentiator

Problem solved

Functional benefit

Products and services

• MEDCAN Branded Medicinal Cannabis Products TGO93 compliant medicinal cannabis products cultivated, manufactured and distributed by Medcan Australia for various medical indications; sold to pharmacies and via prescribers for dispensing to patients.
• Cultivation Services Indoor cultivation using automated processes controlling humidity, temperature, VPD, CO2, fertigation mix and light intensity to deliver consistent, year-round medicinal cannabis production.
• GMP Manufacturing Services Good Manufacturing Practice pharmaceutical manufacturing ensuring products meet the highest standard of pharmaceutical manufacture with robust Quality Management Systems, validation data, and product stability.
• Pharmaceutical Wholesale Distribution QLD Health licensed pharmaceutical wholesaling and distribution supplying pharmacies across Australia with medicinal cannabis products; capable of supporting up to 6,000kgs of dried finished product annually.

Quantifiable outcome

• 493% revenue increase in FY20-21
• +4 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• Greensaver DistributioncoreChannel Partner/ Reseller/ Distributor · 1 May 2024Greensaver Distribution is a new subsidiary of Medcan Group that now handles customer orders. Orders transitioned to the Greensaver Distribution e-commerce platform from May 2024. This change enhances customer ordering ability through an improved ordering system.
• Cann I HelpcoreStrategic or Co-development Partner · 26 October 2020Medcan Australia partnered with the doctor-led network Cann I Help to deliver Australia's first Compassionate Access Program. The program subsidizes medications based on clinical need and financial hardship, offering 15%, 30% or 50% subsidies across a range of treatments. Patients undergo initial screening involving doctor assessment of eligibility, medical condition severity, and financial situation.
• GPs and Specialists (CMOS Study)coreStrategic or Co-development Partner · 12 October 2020Medcan Australia participates in CMOS (Cannabis Medicine Observational Study), a cannabis medicine observational study run in collaboration with GPs and specialists around Australia. The study aims to recruit 20,000 Australian patients undergoing treatment with medicinal cannabis. Medcan provides products to prescribing doctors who collect safety and efficacy data for various indications including fibromyalgia, chronic pain syndromes, PTSD, epilepsy and other conditions.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Cann Group Limited: ASX-listed Australian medicinal cannabis company with cultivation, manufacturing and GMP operations; direct competitor across cultivation licences and pharmacy-channel distribution. Directly comparable on business model and Australian regulatory footprint.
• Little Green Pharma: ASX-listed Australian producer of GMP medicinal cannabis flower and oil products, distributing through pharmacy and prescriber channels. Closely comparable in go-to-market (B2B via pharmacies and prescribers) and product scope.
• Althea Group Holdings: Australian medicinal cannabis company with cultivation, manufacturing and a pharmacy/patient platform including Althea Concierge. Direct competitor with overlapping channel strategy (clinicians + pharmacies) and similar regulatory licensing.
• AusCann Group Holdings (now Aruma Labs / Elixinol Wellness): ASX-listed Australian medicinal cannabis cultivator/manufacturer with a focus on pharmaceutical-grade cannabinoid products. Comparable on cultivation licence portfolio and patient-focused product positioning.
• THC Global Group: Australian medicinal cannabis producer with GMP manufacturing, cultivation and offshore production (Tetra Health). Compares to Medcan on vertically integrated cultivation-to-pharmacy model and Australian prescriber distribution.
• ECS Botanics Holdings: ASX-listed Australian hemp/cannabis cultivator with GMP manufacturing and wholesale into therapeutic channels. Comparable as a smaller Australian vertically integrated cannabis producer targeting similar channels.

Emerging players

• Cannatrek (Cannaponics): Australian medicinal cannabis cultivator and manufacturer with TGA and ODC licences, serving prescribers and wholesalers. Comparable to Medcan on licence stack and pharmacy channel focus.
• Zelira Therapeutics: Australia-based cannabinoid medicines company focused on clinically validated formulations and pharmacy distribution. Comparable on patient/prescriber-focused medicinal cannabis business model, though more formulation-led.

Broad incumbents

• Tilray Brands: Large global cannabis producer with established Australian operations supplying medicinal cannabis to pharmacies. A broader incumbent competing in the same Australian pharmacy channel at greater scale.
• Jazz Pharmaceuticals (GW Pharmaceuticals / Sativex): Pharmaceutical company owning approved cannabinoid medicines (Sativex, Epidiolex). A broad incumbent operating in adjacent regulated cannabinoid therapeutics targeting overlapping patient indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/medcanaustralia
• LinkedInlinkedin.com/company/medcan-australia

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medcan Australia